Author(s)

Ikuo Inoue^1*, Ryo Kubota², Shohan Yanagi³, Masumi Akita⁴, Takanari Nakano⁵, Shigehiro Katayama¹, Akira Shimada¹, Mistuhiko Noda¹

¹Department of Endocrinology and Diabetology, Saitama Medical University, Saitama, Japan.
²Department of Health Sciences, Saitama Prefectural University, Saitama, Japan.
³Research and Development Department, Advanced Materials Development Sector, Tokyo Metropolitan Industrial Technology Research Institute, Tokyo, Japan.
⁴Division of Morphological Science, Biomedical Research Center, Saitama Medical University, Saitama, Japan.
⁵Department of Biochemistry, Saitama Medical University, Saitama, Japan.

Aims: There has been no evidence on the effects of evolocumab, protein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, on small size LDL. We observationally investigated the efficacy and side effects of evolocumab on the LDL subfraction particle diameter using PAGE system for lipoprotein analysis. Methods: We defined 30 patients with high-risk hyperlipidemia. As for analysis of LDL subfraction profile, we used polyacrylamide gel electrophoresis three methods: 1) 3% nondenatured poly-acrylamide gel electrophoresis method (3%PAGE), 2) 2% - 16% nondenatured poly-acrylamide gradient gel electro-phoresis method (2% - 16% GGE) and 3) 2.7% - 5% GGE. Evolocumab 140 mg/day administered together with statin significantly improved serum total cholesterol (TC), triglyceride (TG), high-dense lipoprotein-cholesterol (HDL-C), and LDL-C after four-week treatment. Results: TC, TG, HDL-C and LDL-C levels were improved by, respectively, 33%, 20%, 10%, and 54%. The mean LDL size significantly increased from 25.6 ± 0.4 nm to 26.4 ± 0.8 nm. The small dense LDL-cholesterol (sdLDL-C), large buoyant LDL-cholesterol (lbLDL-C), and mid-band lipoprotein-cholesterol were reduced, respectively. Therefore, the preliminary study on this paper can be the first step into a new insight on the world of lipid metabolism. Conclusion: Short-term administration of evolocumab addedons to statin therapy, significantly reduced small size LDL levels.

PCSK9 Inhibitor, Evolocumab, LDL Heterogeneicity, Small Size LDL, 3% PAGE, 2% - 16% GGE

Inoue, I. , Kubota, R. , Yanagi, S. , Akita, M. , Nakano, T. , Katayama, S. , Shimada, A. and Noda, M. (2017) The New Molecular Entity Evolocumab, One Kind of PCSK9 Inhibitor, Reduce Plasma Small Size LDL-Cholesterol Levels by Using a New Standardized Method of Measuring LDL Size. Open Journal of Molecular and Integrative Physiology, 7, 1-23. doi: 10.4236/ojmip.2017.71001.